Biocon Biologics wraps up integration of former Viatris biosimilars business

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars business from Viatris in over 70 countries in emerging markets, effective from July 1, 2023.

The integration represents an increase in the scale and scope of Biocon Biologics’ operations.

This transition comes after the $3.3 billion deal closure in November 2022 and represents the first wave of countries where Viatris’ operations have been fully incorporated into Biocon Biologics. A well-implemented integration plan has enabled a seamless transition of partners, personnel, systems, and processes across these countries.

Biocon Biologics now manages the existing commercialized portfolio of biosimilars in these markets, which were previously handled by Viatris. This portfolio includes bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept. The company plans to work with both existing and new partners to expand its footprint and solidify its business presence in these regions.

Biocon Biologics’ advanced R&D capabilities, superior manufacturing quality, supply chain excellence, and commercial and regulatory expertise will further facilitate its mission to broaden access to a diverse portfolio of biosimilars, meeting patients’ needs. The company aims to be a trusted partner for patients and the healthcare community in these markets.

Biocon Biologics completes integration of acquired biosimilars business from Viatris. Photo courtesy of Biocon.

All biosimilar products previously commercialized by Viatris in various markets, such as bGlargine (Semglee), bPegfilgrastim (Fulphila), bTrastuzumab (Ogivri), bBevacizumab (Abevmy), and the in-licensed product bAdalimumab (Hulio), will continue to cater to the patients’ needs. Many of these products were co-developed with Biocon Biologics and are manufactured at its world-class facilities in India and Malaysia. The diverse portfolio covers key therapeutic areas such as cancer, diabetes, and autoimmune diseases.

Embodying the highest standards of safety, efficacy, and reliability, Biocon Biologics’ products are a testament to the company’s commitment to continue Viatris’ legacy. The company is dedicated to providing patients, partners, and healthcare systems in these markets with high-quality products, services, and support.

Shreehas Tambe — Biocon Biologics CEO and Managing Director said: “The successful integration of Viatris’ biosimilars business to Biocon Biologics in over 70 countries is a significant milestone and marks the beginning of the transition process. Working closely with our partners, Biocon Biologics will now lead commercial operations in these markets and broaden access to patients with our differentiated portfolio of high quality biosimilars.

“This first wave in the transition process comes ahead of plan, thanks to the tireless efforts of our colleagues at both companies, our advisors and partners who worked relentlessly to make this happen.”